Quantcast

Latest NMDA receptor Stories

2010-10-12 18:13:41

A new class of compounds identified by researchers at Emory University School of Medicine could be developed into drugs for the treatment of schizophrenia. The compounds enhance signaling by molecules in the brain called NMDA receptors, which scientists believe are functioning at low levels in people with schizophrenia. Led by Stephen Traynelis, PhD, professor of pharmacology, a team of Emory researchers sifted through thousands of chemicals and found one, called CIQ, which could selectively...

2010-10-05 19:19:04

New neuroscience research by life scientists from UCLA and Australia may potentially help people who have lost their ability to remember due to brain injury or disease. By examining how we learn and store memories, these scientists have shown that the way the brain first captures and encodes a situation or event is quite different from how it processes subsequent similar events. The study is published in the Sept. 29 edition of the online journal PLoS ONE, a publication of the...

2010-08-31 06:30:00

EVANSTON, Ill., Aug. 31 /PRNewswire/ -- Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders, today reported that its clinical stage candidate for the treatment of depression, GLYX-13, and its second-generation NRX-1050 series have been selected for inclusion on Windhover's list of the "Top 10 Most Interesting Neuroscience Projects to Watch." They were chosen by a committee that included Windhover Information, the publishers of IN...

2010-08-18 18:28:57

Sanford-Burnham scientists uncover new clues to the molecular action of memantine, a drug used to treat Alzheimer's disease, that show why side effects are rare Alzheimer's disease destroys brain cells and their connections (called synapses), causing memory loss and other cognitive problems that disrupt work, hobbies and daily life. Symptoms can be alleviated, in part, by the drug memantine (marketed in the United States as Namenda), which is currently FDA-approved to treat moderate-to-severe...

2010-06-17 06:30:00

BOCA RATION, Fla. and EVANSTON, Ill., June 17 /PRNewswire/ -- Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders, today reported that it presented data at the NCDEU 50th Anniversary Meeting showing that its novel mechanism compound GLYX-13 appeared safe in a Phase I trial. GLYX-13 is a glycine site functional partial agonist (GFPA) selective modulator of the NMDA receptor that is being developed initially for use in depression as...

2010-02-10 06:00:00

EVANSTON, Ill., Feb. 10 /PRNewswire/ -- Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13. GLYX-13 is a GFPA selective modulator of the NMDA receptor. It is initially being developed as a therapy for treatment-resistant depression in severely...

2010-01-27 16:21:21

Scientists at the Brain Research Centre and Centre for Molecular Medicine and Therapeutics have uncovered a key cellular mechanism that alters brain cell function in Huntington's disease, and identified a possible treatment for the disease. The results of the study were published online today and will appear in the January 28 edition of the journal Neuron. Huntington's disease is an inherited degenerative brain disease that causes cognitive and motor impairment, and eventually death. One in...

2010-01-21 20:34:05

For the first time, research led by Youming Lu, PhD, MD, Professor of Neurology and Neuroscience at LSU Health Sciences Center New Orleans School of Medicine, has identified a novel mechanism that may trigger brain damage during stroke and identified a therapeutic approach to block it. The work, funded by the National Institute on Aging (NIA) and the National Institute of Neurological Disorders and Stroke (NINDS), both of the National Institutes of Health (NIH), as well as the American Heart...

2010-01-21 17:01:08

Biomedical scientists from the University of Central Florida and Louisiana State University have identified a way to block a "cell death signal" that they believe triggers brain damage during strokes. Strokes, also known as cerebral ischemia, are caused by inadequate blood flow to the brain and are the third-leading cause of death in the United States. The team's work focused on a neurotransmitter that typically plays an important role in communication among nerve cells in the brain and...

2009-12-16 06:45:00

EVANSTON, Ill., Dec. 16 /PRNewswire/ -- Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA receptor modulators, today announced that it has initiated a Phase I clinical trial of its lead compound GLYX-13 and has successfully dosed the first subjects in the study. GLYX-13, a glycine site functional partial agonist (GFPA) selective modulator of the NMDA receptor, is initially being developed as a...


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related